Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

740.78 -8.66 (-1.15%)

Streaming Delayed Price Updated: 3:44 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

59 60 Next >

Wednesday's session: top gainers and losers in the S&P500 index ↗

October 01, 2025

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.

Via Chartmill

Health Care Stocks Rally, Nike Beats The Street: What's Moving Markets Wednesday? ↗

October 01, 2025

Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps markets afloat.

Via Benzinga

Which S&P500 stocks are moving on Wednesday? ↗

October 01, 2025

Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.

Via Chartmill

Nvidia, Amphenol, Lockheed Martin And A Health Care Stock On CNBC's 'Final Trades' ↗

October 01, 2025

Nvidia surges past 52-week high, surpasses $4.5 trillion market cap as tech companies invest in AI. Regeneron and Amphenol named as top trades.

Via Benzinga

Topics Artificial Intelligence

Acuity, Lithium Americas, Rezolve AI, AES And Other Big Stocks Moving Higher On Wednesday ↗

October 01, 2025

Via Benzinga

Topics Artificial Intelligence

Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025

September 30, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

2 Beaten-Down Stocks to Buy and Hold for a Decade ↗

September 30, 2025

These biotechs should benefit from their innovative ways.

Via The Motley Fool

Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes

September 29, 2025

Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by...

Via MarketMinute

1 Healthcare Stock with Exciting Potential and 2 We Ignore

September 29, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This...

Via StockStory

Topics Stocks

FDA Expands Use Of Regeneron's Evkeeza To Infants With Rare Cholesterol Disorder ↗

September 26, 2025

The U.S.

Via Benzinga

Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol

September 26, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Why Regeneron (REGN) Shares Are Falling Today

September 25, 2025

Shares of biotech company Regeneron (NASDAQ:REGN) fell 4.1% in the afternoon session after the company highlighted challenges, including regulatory approvals and competitive pressures, at a healthcare...

Via StockStory

Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch ↗

September 25, 2025

On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began.

Via Benzinga

1 Safe-and-Steady Stock on Our Watchlist and 2 We Question

September 25, 2025

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Via StockStory

What Does the Market Think About Regeneron Pharmaceuticals? ↗

September 24, 2025

Via Benzinga

Why Regeneron (REGN) Stock Is Down Today

September 23, 2025

Shares of biotech company Regeneron (NASDAQ:REGN) fell 4.8% in the afternoon session after a court ruling in Australia dealt a blow to the company's efforts to block a competing version of its...

Via StockStory

Wall Street Pauses For A Breather, Small Caps Soar: What's Moving Markets Tuesday? ↗

September 23, 2025

Wall Street paused on Tuesday after three straight sessions of strong gains that pushed major large-cap indices to fresh records.

Via Benzinga

Discover which S&P500 stocks are making waves on Tuesday. ↗

September 23, 2025

Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.

Via Chartmill

Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection ↗

September 23, 2025

FDA cites Catalent Indiana issues in Scholar Rock's SMA drug review; European approval decision expected in 2026, with Germany as the launch market.

Via Benzinga

Tuesday's session: gap up and gap down stock in the S&P500 index ↗

September 23, 2025

Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Tuesday and stay ahead of the market trends.

Via Chartmill

1 S&P 500 Stock on Our Buy List and 2 We Turn Down

September 23, 2025

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,...

Via StockStory

Topics Stocks

FDA Delays Key Sanofi Multiple Sclerosis Drug Decision ↗

September 22, 2025

Sanofi's tolebrutinib review for non-relapsing multiple sclerosis has been extended by the FDA until December 2025.

Via Benzinga

Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion

September 22, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

REGENERON PHARMACEUTICALS (NASDAQ:REGN) Screens as a Top Value Stock with Strong Fundamentals ↗

September 20, 2025

Regeneron Pharmaceuticals (REGN) is a top value stock with a low P/E ratio, strong profitability, and excellent financial health, offering a potential margin of safety for investors.

Via Chartmill

Can Regeneron Change The Paradigm In Multiple Myeloma — And Undercut J&J? ↗

September 19, 2025

The company is looking to take on Johnson & Johnson in treating patients with a precursor to multiple myeloma.

Via Investor's Business Daily

Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks

September 19, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

1 Cash-Heavy Stock to Research Further and 2 We Brush Off

September 19, 2025

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining...

Via StockStory

Regeneron Touts Positive Data From Phase 3 Study In Patients With Ultra-Rare Genetic Disorder ↗

September 17, 2025

Regeneron's Phase 3 trial of garetosmab showed a 90%+ reduction in new bone lesions for FOP, with no deaths and good safety over 56 weeks.

Via Benzinga

Topics Death

Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD

September 17, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation

September 17, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

59 60 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.